Journal article
Strut-based accelerated partial breast irradiation: Report of treatment results for 250 consecutive patients at 5 years from a multicenter retrospective study
Brachytherapy, v 15(6), pp 780-787
Nov 2016
PMID: 27528591
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
This registry trial studied the long-term outcomes of women receiving accelerated partial breast irradiation (APBI) using strut-based applicators and reports on the local control, toxicity, and survival for the first 250 patients treated with this device.
Patients were treated using the strut-based brachytherapy device with conventional dose and fractionation of 34 Gy in 10 twice-daily fractions. Planning goals for the planning target volume were V90 > 90%, V150 < 50 cc, and V200 < 20 cc. Toxicity was graded based on the Common Terminology Criteria for Adverse Events v3.0. Recurrence rates were also calculated.
Median followup was 59.5 months for the 250 patients. Grade 2 or higher adverse events at any time for hyperpigmentation, induration, erythema, telangiectasia, breast pain, seroma, and fat necrosis were 0.4%, 3.0%, 3.0%, 3.0%, 3.9%, 4.8%, and 1.3%, respectively. The median V90 was 97%, V95 was 95.1%, V150 was 28.7 cc, and V200 was 14.2 cc. For those patients with a less than a 5-mm or 3-mm-skin bridge, the median skin max doses were 272 and 289 cGy, respectively. The 4-year actuarial recurrence rates for true recurrence/marginal miss and ipsilateral breast tumor recurrence were 2.3% and 3.6%, respectively. The 4-year actuarial rates for overall survival, cause-specific survival, and disease-free survival were 97%, 98%, and 92%, respectively.
The strut-based applicator was designed to simplify APBI compared to interstitial brachytherapy. This report confirms excellent tumor control and survival with low toxicity and supports the evidence that brachytherapy has less normal tissue toxicity than APBI with external beam irradiation.
Metrics
Details
- Title
- Strut-based accelerated partial breast irradiation: Report of treatment results for 250 consecutive patients at 5 years from a multicenter retrospective study
- Creators
- Catheryn Yashar - University of California, San DiegoDeanna Attai - UCLA HealthErnest Butler - Wheeling HospitalJohn Einck - University of California, San DiegoSteven Finkelstein - 21st Century OncologyBen Han - South Florida Radiation Oncology, Boynton Beach, FL.Robert Hong - Virginia Hospital CenterLydia Komarnicky - Drexel UniversityMaureen Lyden - BioStat International, Inc., Tampa, FL.Constantine Mantz - 21st Century OncologySerban Morcovescu - Texas OncologyStephen Nigh - Northwest Community HospitalKerri Perry - Kerri Perry MD Denton, TX.Jondavid Pollock - Wheeling HospitalJay Reiff - Drexel UniversityDaniel Scanderbeg - University of California, San DiegoMargaret Snyder - Arizona Pain SpecialistsRobert Kuske - Arizona Pain Specialists
- Publication Details
- Brachytherapy, v 15(6), pp 780-787
- Publisher
- Elsevier
- Grant note
- Cianna Medical, Inc
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine); [Retired Faculty]
- Web of Science ID
- WOS:000389864100015
- Scopus ID
- 2-s2.0-84995593451
- Other Identifier
- 991019168185104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging